Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T64682
|
||||
| Former ID |
TTDR01250
|
||||
| Target Name |
Serine/threonine-protein kinase Sgk1
|
||||
| Gene Name |
SGK1
|
||||
| Synonyms |
Serum/glucocorticoid-regulated kinase 1; SGK1
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Prostate cancer [ICD9: 185; ICD10: C61] | ||||
| BioChemical Class |
Kinase
|
||||
| Target Validation |
T64682
|
||||
| UniProt ID | |||||
| EC Number |
EC 2.7.11.1
|
||||
| Sequence |
MTVKTEAAKGTLTYSRMRGMVAILIAFMKQRRMGLNDFIQKIANNSYACKHPEVQSILKI
SQPQEPELMNANPSPPPSPSQQINLGPSSNPHAKPSDFHFLKVIGKGSFGKVLLARHKAE EVFYAVKVLQKKAILKKKEEKHIMSERNVLLKNVKHPFLVGLHFSFQTADKLYFVLDYIN GGELFYHLQRERCFLEPRARFYAAEIASALGYLHSLNIVYRDLKPENILLDSQGHIVLTD FGLCKENIEHNSTTSTFCGTPEYLAPEVLHKQPYDRTVDWWCLGAVLYEMLYGLPPFYSR NTAEMYDNILNKPLQLKPNITNSARHLLEGLLQKDRTKRLGAKDDFMEIKSHVFFSLINW DDLINKKITPPFNPNVSGPNDLRHFDPEFTEEPVPNSIGKSPDSVLVTASVKEAAEAFLG FSYAPPTDSFL |
||||
| Structure |
2R5T; 3HDM; 3HDN
|
||||
| Drugs and Mode of Action | |||||
| Drug(s) | CI-1040 | Drug Info | Phase 2 | Discovery agent | [1], [2] |
| Inhibitor | 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole | Drug Info | [3] | ||
| CGP-57380 | Drug Info | [4] | |||
| CI-1040 | Drug Info | [5] | |||
| GF-109203 | Drug Info | [5] | |||
| GSK-650394 | Drug Info | [6] | |||
| KN-62 | Drug Info | [5] | |||
| RO-316233 | Drug Info | [5] | |||
| Pathways | |||||
| KEGG Pathway | FoxO signaling pathway | ||||
| PI3K-Akt signaling pathway | |||||
| Aldosterone-regulated sodium reabsorption | |||||
| NetPath Pathway | IL5 Signaling Pathway | ||||
| FSH Signaling Pathway | |||||
| IL2 Signaling Pathway | |||||
| Pathway Interaction Database | Insulin Pathway | ||||
| Glucocorticoid receptor regulatory network | |||||
| mTOR signaling pathway | |||||
| FoxO family signaling | |||||
| Class I PI3K signaling events | |||||
| Reactome | Stimuli-sensing channels | ||||
| WikiPathways | Insulin Signaling | ||||
| Iron uptake and transport | |||||
| FSH signaling pathway | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00033384) CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer. U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5676). | ||||
| REF 3 | J Med Chem. 2004 Dec 2;47(25):6239-47.Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. | ||||
| REF 4 | Biochem J. 2007 Dec 15;408(3):297-315.The selectivity of protein kinase inhibitors: a further update. | ||||
| REF 5 | Biochem J. 2000 Oct 1;351(Pt 1):95-105.Specificity and mechanism of action of some commonly used protein kinase inhibitors. | ||||
| REF 6 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8040). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.